These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8359571)

  • 21. Use of octreotide in the treatment of digestive neuroendocrine tumours. Seven year experience in 20 cases including 9 cases of metastatic midgut carcinoid and 5 cases of metastatic gastrinoma.
    Fiasse R; Pauwels S; Rahier J; Jamar F; Ketelslegers JM; Hassoun A; de Longueville M
    Acta Gastroenterol Belg; 1993; 56(3-4):279-91. PubMed ID: 8266771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of octreotide acetate for control of symptoms in patients with islet cell tumors.
    Maton PN
    World J Surg; 1993; 17(4):504-10. PubMed ID: 8395751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Somatostatin analogue in the treatment of neuroendocrine gut tumors].
    Ben Yosef R; Glaser B; Catane R
    Harefuah; 1990 Jul; 119(1-2):15-8. PubMed ID: 2172125
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of somatostatin analog in management of carcinoid syndrome.
    Vinik A; Moattari AR
    Dig Dis Sci; 1989 Mar; 34(3 Suppl):14S-27S. PubMed ID: 2920654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of somatostatin, octreotide and pitressin plus nitroglycerine on systemic and portal haemodynamics in the control of acute variceal bleeding.
    Zhang HB; Wong BC; Zhou XM; Guo XG; Zhao SJ; Wang JH; Wu KC; Ding J; Lam SK; Fan DM
    Int J Clin Pract; 2002; 56(6):447-51. PubMed ID: 12166543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 111In-octreotide scintigraphy in oncology.
    Krenning EP; Kwekkeboom DJ; Reubi JC; van Hagen PM; van Eijck CH; Oei HY; Lamberts SW
    Digestion; 1993; 54 Suppl 1():84-7. PubMed ID: 8359573
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study.
    Bajetta E; Catena L; Fazio N; Pusceddu S; Biondani P; Blanco G; Ricci S; Aieta M; Pucci F; Valente M; Bianco N; Mauri CM; Spada F
    Cancer; 2014 Aug; 120(16):2457-63. PubMed ID: 24752410
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.
    Cives M; Strosberg J
    Drugs; 2015 May; 75(8):847-58. PubMed ID: 25911185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of type I gastric neuroendocrine tumors with somatostatin analogs.
    Khuroo MS; Khuroo MS; Khuroo NS
    J Gastroenterol Hepatol; 2010 Mar; 25(3):548-54. PubMed ID: 20074162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor imaging and therapy using radiolabeled somatostatin analogues.
    de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
    Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Neuroendocrine tumors of the gastrointestinal tract].
    Arnold C
    Praxis (Bern 1994); 2007 Jan; 96(1-2):19-28. PubMed ID: 17256557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of octreotide in the treatment of gastroenteropancreatic endocrine tumors.
    Degen L; Beglinger C
    Digestion; 1999; 60 Suppl 2():9-14. PubMed ID: 10207226
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid.
    Raderer M; Kurtaran A; Scheithauer W; Fiebiger W; Weinlaender G; Oberhuber G
    Oncology; 2001; 60(2):141-5. PubMed ID: 11244329
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Somatostatin analog (octreotide) in clinical use: current and potential indications].
    Meier R; Dierdorf R; Gyr K
    Schweiz Med Wochenschr; 1992 Jun; 122(25):957-68. PubMed ID: 1621078
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Somatostatin or octreotide in acute variceal bleeding.
    Hadengue A
    Digestion; 1999; 60 Suppl 2():31-41. PubMed ID: 10207229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Octreotide and bleeding oesophageal varices: new indication. Nothing new.
    Prescrire Int; 1999 Aug; 8(42):113-4. PubMed ID: 11503829
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sandostatin and the Belfast experience.
    Buchanan KD; Collins JS; Varghese A; Johnston CF; Shaw C
    Digestion; 1990; 45 Suppl 1():11-4; discussion 15-6. PubMed ID: 2159429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potential indications for octreotide in gastroenterology: summary of workshop.
    Burroughs AK; Malagelada R
    Digestion; 1993; 54 Suppl 1():59-67. PubMed ID: 8359570
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage.
    Seo YS; Park SY; Kim MY; Kim JH; Park JY; Yim HJ; Jang BK; Kim HS; Hahn T; Kim BI; Heo J; An H; Tak WY; Baik SK; Han KH; Hwang JS; Park SH; Cho M; Um SH
    Hepatology; 2014 Sep; 60(3):954-63. PubMed ID: 24415445
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Endocrine-active gastrointestinal tumors: are there any new therapeutic possibilities?].
    Marbet UA; Kraenzlin M; Gyr K; Stalder GA
    Dtsch Med Wochenschr; 1986 Jul; 111(28-29):1120-3. PubMed ID: 2426077
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.